Investigational · not FDA approved

Editorially reviewed · Last updated June 2026 · How we review

Retatrutide and Sleep Apnea (Obstructive Sleep Apnea)

Q: Does retatrutide treat sleep apnea?

There is no published data yet on retatrutide's effect on sleep apnea specifically. The TRIUMPH-1 trial includes a nested OSA sub-study, with results expected in 2026. Given retatrutide's substantial weight loss effects and the established relationship between weight loss and OSA improvement, there is strong reason to expect positive results — but we need to wait for the data.

Q: Will retatrutide be approved for sleep apnea?

Eli Lilly has stated that it plans to include OSA data in its regulatory submissions for retatrutide. Whether the FDA grants an OSA-specific indication will depend on the TRIUMPH-1 sub-study results. The precedent is favorable — Zepbound (tirzepatide) was approved for OSA in 2024 based on similar trial data.

Q: Should I wait for retatrutide instead of starting CPAP?

No. If you have been diagnosed with moderate or severe sleep apnea, you should begin treatment with the options available now. Untreated OSA increases cardiovascular risk, impairs quality of life, and increases accident risk. CPAP is highly effective when used consistently. Tirzepatide (Zepbound) is also available now for OSA in adults with obesity. Retatrutide will not be available by prescription until at least 2027.

Q: How much weight loss is needed to improve sleep apnea?

The relationship is roughly linear: every 1% of body weight lost is associated with an approximate 3% reduction in AHI. For many patients, 10-15% weight loss can produce clinically meaningful improvement. At 20%+ weight loss, a significant proportion of patients see OSA resolve entirely or improve to a level where CPAP may no longer be necessary.

Q: Does retatrutide affect sleep or cause insomnia?

Retatrutide trials have not reported sleep disturbance or insomnia as adverse events. In the Phase 2 obesity program and the MASLD sub-study, the most frequently reported adverse events were "transient and generally mild-to-moderate gastrointestinal events" — nausea, diarrhea, vomiting and constipation — which were dose-related rather than sleep-related. The drug's effect on sleep is therefore mostly indirect and tends to be favorable: weight loss reduces obstructive sleep apnea severity, and reviews note that "in aggregate, the data showed a greater degree of sleep apnea improvement (as judged by the apnea hypopnea index) with greater weight reduction, regardless of how it was achieved." Incretin drugs also have central nervous system activity (at the carotid body, hypothalamus, and on orexin signalling involved in sleep-wake regulation), so some of the sleep benefit may go beyond weight loss alone. The one on-treatment caveat to be aware of is retatrutide's dose-dependent increase in resting heart rate, which peaks around week 24 and then declines — if a faster resting pulse is disrupting your rest, raise it with your prescriber. No retatrutide-specific sleep-quality outcomes have been published yet; the TRIUMPH-1 nested OSA sub-study (results expected 2026) will be the first dedicated sleep data.

Obstructive sleep apnea (OSA) is one of the most common and underdiagnosed consequences of obesity. It occurs when excess tissue in the upper airway collapses during sleep, causing repeated breathing interruptions. OSA affects an estimated 30-40% of adults with obesity, worsens cardiovascular risk, impairs quality of life, and increases daytime fatigue and mortality.

Weight loss is the single most effective non-surgical intervention for OSA. Every 1% of body weight lost is associated with an approximate 3% reduction in the apnea-hypopnea index (AHI), the primary measure of sleep apnea severity. Given that retatrutide has demonstrated weight loss of up to 28.7% in Phase 3 trials, its potential impact on OSA is substantial.

No retatrutide-specific OSA data has been published yet. The TRIUMPH-1 Phase 3 trial includes a nested OSA sub-study, with results expected in 2026. This page covers what we know, what we expect, and the relevant precedent from tirzepatide's OSA trial.

Retatrutide is an investigational drug that has not been approved by the FDA.

The TRIUMPH-1 OSA Sub-Study

Trial design

The pivotal TRIUMPH-1 Phase 3 trial is structured as a basket trial with nested protocols for multiple conditions, including obstructive sleep apnea. A trial design paper was published in Diabetes, Obesity and Metabolism in October 2025.

Detail	Value
Parent trial	TRIUMPH-1
Total participants	~2,300+ (across TRIUMPH-1 and TRIUMPH-2)
Duration	72 weeks
OSA sub-study	Nested protocol within TRIUMPH-1
Likely endpoints	Change in AHI, OSA severity classification, CPAP discontinuation rates
Status	Active — results expected 2026

The nested design means that participants who have both obesity and diagnosed OSA will have their sleep apnea metrics tracked as part of the larger trial. This is an efficient approach — it generates OSA-specific data without requiring a separate standalone trial.

What we expect to learn

AHI reduction — the primary measure of how many times per hour breathing stops or significantly decreases during sleep
Shift in OSA severity — whether participants move from severe to moderate, moderate to mild, or achieve full resolution
CPAP use — whether weight loss on retatrutide allows patients to discontinue continuous positive airway pressure (CPAP) therapy
Sleep quality metrics — patient-reported outcomes on daytime sleepiness and sleep quality

Why Weight Loss Improves Sleep Apnea

OSA is fundamentally a mechanical problem: excess fat deposits around the upper airway — particularly in the neck, tongue, and pharynx — narrow the airway. During sleep, when muscle tone decreases, this narrowed airway is more likely to collapse.

Weight loss reduces these fat deposits, widening the airway and reducing the frequency and severity of obstructive events. The relationship is well-established:

10% weight loss typically produces a ~26% reduction in AHI
15-20% weight loss can move many patients from severe to mild OSA, or from mild to resolution
Bariatric surgery (which produces 20-30% weight loss) has been shown to resolve OSA in a significant proportion of patients

Retatrutide's 28.7% mean weight loss at the 12mg dose in TRIUMPH-4 is in the range typically associated with substantial OSA improvement or resolution.

Precedent: Tirzepatide's SURMOUNT-OSA Trial

The most direct precedent for a GLP-1 class drug treating OSA comes from tirzepatide's SURMOUNT-OSA trial, results of which were published in 2024.

SURMOUNT-OSA key results

Outcome	Tirzepatide	Placebo
AHI reduction	~50-60%	~5%
Weight loss	~18-20%	~2%
Patients no longer meeting OSA criteria	~40-50%	~10%

The SURMOUNT-OSA results were strong enough that Eli Lilly submitted tirzepatide for an OSA-specific indication, and the FDA approved Zepbound for moderate-to-severe OSA in adults with obesity in 2024. This was the first drug approved specifically for sleep apnea.

What this means for retatrutide

SURMOUNT-OSA establishes two important precedents:

The FDA will approve a weight loss drug for an OSA indication — this is no longer hypothetical
The relationship between weight loss and AHI reduction is consistent and predictable — if retatrutide produces greater weight loss than tirzepatide, it is reasonable to expect at least comparable (and potentially greater) OSA improvement

Lilly has confirmed that it plans to submit retatrutide data supporting an OSA indication as part of its regulatory filings.

Understanding Sleep Apnea Severity

The Apnea-Hypopnea Index (AHI)

AHI measures the number of apneas (complete breathing cessations) and hypopneas (partial breathing reductions) per hour of sleep. It is the standard metric for diagnosing and grading OSA.

AHI Range	Severity	Clinical Significance
<5	Normal	No clinically significant sleep apnea
5-14	Mild	Increased daytime sleepiness; may or may not require treatment
15-29	Moderate	Significant daytime impairment; CPAP typically recommended
≥30	Severe	High cardiovascular risk; CPAP strongly recommended

Why AHI reduction matters

Reducing AHI translates directly to fewer breathing interruptions per night. This improves:

Oxygen saturation — fewer episodes of low blood oxygen during sleep
Sleep architecture — fewer arousals means more restorative deep sleep
Daytime function — reduced fatigue, improved concentration, lower accident risk
Cardiovascular risk — untreated severe OSA is associated with increased risk of hypertension, atrial fibrillation, heart failure, and stroke

The Broader TRIUMPH OSA Strategy

OSA sub-studies are nested within both TRIUMPH-1 and TRIUMPH-2 (the T2D obesity trial). This dual-population approach means Lilly will have OSA data in:

Patients with obesity without diabetes (TRIUMPH-1)
Patients with obesity and type 2 diabetes (TRIUMPH-2)

Both populations have high OSA prevalence, and having data in both strengthens the case for a broad OSA indication.

Current Treatment Options for OSA

While waiting for retatrutide, people with OSA have several established treatment options:

CPAP therapy

Continuous positive airway pressure remains the gold standard for OSA treatment. It is highly effective but has well-documented adherence challenges — many patients find the mask uncomfortable and do not use it consistently.

Tirzepatide (Zepbound)

As of 2024, tirzepatide is the first and only drug specifically approved for moderate-to-severe OSA in adults with obesity. It is available by prescription now and represents a pharmaceutical alternative or complement to CPAP.

Weight loss (any method)

Any form of sustained weight loss — lifestyle changes, other medications, bariatric surgery — can improve OSA. The magnitude of improvement correlates with the amount of weight lost.

Oral appliances and surgery

Mandibular advancement devices and surgical interventions (such as uvulopalatopharyngoplasty) are options for some patients, particularly those who cannot tolerate CPAP or are not candidates for weight loss medications.

Frequently Asked Questions

Does retatrutide treat sleep apnea?

There is no published data yet on retatrutide's effect on sleep apnea specifically. The TRIUMPH-1 trial includes a nested OSA sub-study, with results expected in 2026. Given retatrutide's substantial weight loss effects and the established relationship between weight loss and OSA improvement, there is strong reason to expect positive results — but we need to wait for the data.

Will retatrutide be approved for sleep apnea?

Eli Lilly has stated that it plans to include OSA data in its regulatory submissions for retatrutide. Whether the FDA grants an OSA-specific indication will depend on the TRIUMPH-1 sub-study results. The precedent is favorable — Zepbound (tirzepatide) was approved for OSA in 2024 based on similar trial data.

Should I wait for retatrutide instead of starting CPAP?

No. If you have been diagnosed with moderate or severe sleep apnea, you should begin treatment with the options available now. Untreated OSA increases cardiovascular risk, impairs quality of life, and increases accident risk. CPAP is highly effective when used consistently. Tirzepatide (Zepbound) is also available now for OSA in adults with obesity. Retatrutide will not be available by prescription until at least 2027.

How much weight loss is needed to improve sleep apnea?

The relationship is roughly linear: every 1% of body weight lost is associated with an approximate 3% reduction in AHI. For many patients, 10-15% weight loss can produce clinically meaningful improvement. At 20%+ weight loss, a significant proportion of patients see OSA resolve entirely or improve to a level where CPAP may no longer be necessary.

Does retatrutide affect sleep or cause insomnia?

Retatrutide trials have not reported sleep disturbance or insomnia as adverse events. In the Phase 2 obesity program and the MASLD sub-study, the most frequently reported adverse events were "transient and generally mild-to-moderate gastrointestinal events" — nausea, diarrhea, vomiting and constipation — which were dose-related rather than sleep-related. The drug's effect on sleep is therefore mostly indirect and tends to be favorable: weight loss reduces obstructive sleep apnea severity, and reviews note that "in aggregate, the data showed a greater degree of sleep apnea improvement (as judged by the apnea hypopnea index) with greater weight reduction, regardless of how it was achieved." Incretin drugs also have central nervous system activity (at the carotid body, hypothalamus, and on orexin signalling involved in sleep-wake regulation), so some of the sleep benefit may go beyond weight loss alone. The one on-treatment caveat to be aware of is retatrutide's dose-dependent increase in resting heart rate, which peaks around week 24 and then declines — if a faster resting pulse is disrupting your rest, raise it with your prescriber. No retatrutide-specific sleep-quality outcomes have been published yet; the TRIUMPH-1 nested OSA sub-study (results expected 2026) will be the first dedicated sleep data.

Sources

TRIUMPH trial design paper. Diabetes, Obesity and Metabolism. October 2025. DOI: 10.1111/dom.70209
Eli Lilly and Company. (2025). Lilly's retatrutide achieved significant weight loss and pain relief in adults with obesity and knee osteoarthritis. Press release.
Malhotra, A., et al. (2024). Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). New England Journal of Medicine.
Retatrutide for MASLD — Phase 2a trial (gastrointestinal events the most frequent adverse events; no sleep-related adverse events reported). PMC11271400
GLP-1 / GIP receptor agonists in obstructive sleep apnea and obesity — review (AHI improvement tracks weight loss; incretin CNS activity at the carotid body, hypothalamus and on orexin). PMC12289732
ClinicalTrials.gov: Retatrutide trials

Questions to ask your doctor

Is a GLP-1 medication an appropriate option for my condition specifically?
What does the evidence actually show for my condition, versus weight loss alone?
What are the alternatives, and how do they compare for me?
What risks or monitoring apply given my health history?
What results would be realistic, and over what timeframe?

How we keep this honest

What this is: Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
Regulatory status: Retatrutide and similar peptides are investigational — not approved by the FDA or any regulator. Semaglutide and tirzepatide are prescription-only medicines, available only through a licensed prescriber.
Our standard: Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
No commercial ties: We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.

Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.

Sources